Jeff Johnson
Stock Analyst at Baird
(4.65)
# 201
Out of 5,090 analysts
150
Total ratings
58.82%
Success rate
28.59%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| COO The Cooper Companies | Maintains: Outperform | $85 → $98 | $81.40 | +20.39% | 19 | Dec 5, 2025 | |
| ALC Alcon | Maintains: Outperform | $95 → $98 | $80.73 | +21.39% | 11 | Nov 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $112 → $90 | $65.49 | +37.43% | 15 | Sep 26, 2025 | |
| BBNX Beta Bionics | Maintains: Neutral | $15 → $17 | $29.38 | -42.14% | 2 | Jul 30, 2025 | |
| HSIC Henry Schein | Downgrades: Neutral | $82 → $72 | $73.62 | -2.20% | 10 | Jul 14, 2025 | |
| NVST Envista Holdings | Upgrades: Outperform | $21 → $23 | $20.23 | +13.69% | 10 | May 27, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $94.28 | +21.98% | 14 | May 6, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $20.92 | +14.72% | 16 | May 1, 2025 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $364.02 | +11.26% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $157.21 | +75.56% | 18 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $304.49 | -21.84% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $27.02 | +159.07% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.42 | +323.02% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $11.25 | +495.56% | 6 | Feb 18, 2022 |
The Cooper Companies
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $98
Current: $81.40
Upside: +20.39%
Alcon
Nov 13, 2025
Maintains: Outperform
Price Target: $95 → $98
Current: $80.73
Upside: +21.39%
DexCom
Sep 26, 2025
Maintains: Outperform
Price Target: $112 → $90
Current: $65.49
Upside: +37.43%
Beta Bionics
Jul 30, 2025
Maintains: Neutral
Price Target: $15 → $17
Current: $29.38
Upside: -42.14%
Henry Schein
Jul 14, 2025
Downgrades: Neutral
Price Target: $82 → $72
Current: $73.62
Upside: -2.20%
Envista Holdings
May 27, 2025
Upgrades: Outperform
Price Target: $21 → $23
Current: $20.23
Upside: +13.69%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $94.28
Upside: +21.98%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $20.92
Upside: +14.72%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $364.02
Upside: +11.26%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $157.21
Upside: +75.56%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $304.49
Upside: -21.84%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $27.02
Upside: +159.07%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.42
Upside: +323.02%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $11.25
Upside: +495.56%